Jim Cramer Notes 'It's Been Hard to Own Apple Lately'
Apple Inc. (NASDAQ:AAPL) is one of the 11 stocks on Jim Cramer's radar. Cramer started his game plan for the week with Apple Inc. (NASDAQ:AAPL) as he touched on the impact of the president's tariff policies on the company.
'Apple stock just had a second straight positive week. That's an unusual occurrence of late, and some of the newfound luster might be in anticipation of Monday's Worldwide Developers Conference. Now… remember, this is a software event, not a hardware event, so they're not going to unveil new hardware, and it's usually not a catalyst for the stock to move.
A wide view of an Apple store, showing the range of products the company offers.
Apple Inc. (NASDAQ:AAPL) designs and sells various consumer tech products. The company also provides digital services through subscriptions like Apple Music, Apple TV+, and Apple Arcade. It runs key platforms such as the App Store and Apple Pay.
While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
19 minutes ago
- Associated Press
Wall Street's rally stalls as US stocks dip for their 1st loss in 4 days
NEW YORK (AP) — Wall Street's rally stalled on Wednesday after U.S. stocks climbed back within 2% of their all-time high. The S&P 500 fell 0.3% for its first loss in four days. The Dow Jones Industrial Average was virtually unchanged after edging down by 1 point, and the Nasdaq composite slipped 0.5%. Several Big Tech stocks led the way lower, and a 1.9% drop for Apple was the heaviest weight on the market. It's been listless this week after unveiling several modest upcoming changes to the software that runs its devices. The action was stronger in the bond market, where Treasury yields eased after a report suggested President Donald Trump's tariffs are not pushing inflation much higher, at least not yet. U.S. consumers had to pay prices for food, gasoline and other costs of living that were 2.4% higher overall in May than a year earlier. That was up from April's 2.3% inflation rate, but it wasn't as bad as the 2.5% that Wall Street was expecting. A fear has been that Trump's wide-ranging tariffs could ignite an acceleration in inflation, just when it had seemed to get nearly all the way back to the Federal Reserve's 2% target from more than 9% three summers ago. It hasn't happened, though economists warn it may take months more to feel the full effect of Trump's tariffs. 'Another month goes by with little evidence of tariffs, but the longer-term inflation challenge they pose remain,' according to Ellen Zentner, chief economic strategist for Morgan Stanley Wealth Management. Financial markets also had only modest reactions to the conclusion of two days of trade talks between the United States and China in London. Trump said Wednesday that China will supply rare-earth minerals and magnets to the United States, while his government will allow Chinese students into U.S. universities in a deal that still needs an agreement by him and by China's leader. Trump also said that 'President XI and I are going to work closely together to open up China to American Trade. This would be a great WIN for both countries!!!' Investors are still hoping for a more sweeping trade deal that would ease tensions between the world's two largest economies. Hopes for such deals between the United States and countries around the world have been one of the main reasons the S&P 500 has charged nearly all the way back to its all-time high after dropping roughly 20% below a couple months ago. Without them, the fear is that Trump's high tariffs could drive the economy into a recession while pushing inflation higher. The S&P 500 is now sitting 2% below its record. On Wall Street, Chewy dropped 11% after the seller of pet supplies reported a weaker profit for the latest quarter than analysts had forecast. Expectations were high after its stock had already rallied nearly 37% coming into the day for the year so far. Tesla swung between gains and losses before finishing with a rise of 0.1% to continue its shaky run. It's been recovering much of its big losses taken last week after Elon Musk's relationship with Trump imploded, which in turn raised fears about a loss of business for the electric-vehicle company. Musk on Wednesday backed away from some of his earlier comments and said they went 'too far.' All told, the S&P 500 fell 16.57 points to 6,022.24. The Dow Jones Industrial Average slipped 1.10 to 42,865.77, and the Nasdaq composite sank 99.11 to 19,615.88. In the bond market, the yield on the 10-year Treasury eased to 4.41% from 4.47% late Tuesday. Shorter-term yields, which more closely track expectations for what the Fed will do with overnight interest rates, fell more. Wednesday's better-than-expected reading on inflation raised expectations along Wall Street that the Fed could cut its main interest rate at least twice by the end of the year. The Fed has been keeping interest rates steady so far this year, going on pause after cutting rates at the end of last year. It has been waiting to see how much Trump's tariffs raise inflation because cutting interest rates could push inflation up even more, in addition to giving the economy a boost. 'The Fed could be justified in doing some preemptive rate cuts,' said Brian Jacobsen, chief economist at Annex Wealth Management. 'They were afraid that inflation would rise before growth would slow, but the script has been flipped and they will likely change their tune.' In stock markets abroad, indexes fell across much of Europe after rising in Asia. South Korea's Kospi was one of the best performers and jumped 1.2%. ___ AP Business Writer Yuri Kageyama contributed.
Yahoo
24 minutes ago
- Yahoo
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0) 48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1) KIT related tolerability events demonstrated to be reversible Enrollment to Phase 3 CSU trials ongoing Company to host webcast today at 6:00 pm ET HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival. The data are being presented in a late breaking oral presentation (#100227) at the EAACI Congress 2025. The Company previously announced that this Phase 2 study of barzolvolimab in patients with moderate to severe CSU refractory to antihistamines, including patients with biologic-refractory disease, met its primary endpoint—a significant improvement in UAS7 compared to placebo at 12 weeks—across all dose groups tested. Barzolvolimab also demonstrated rapid, profound complete response rates (UAS7=0; no itch/no hives) in up to 51% of patients at 12 weeks, which continued to deepen over 52 weeks of active therapy to up to 71% of patients. Seven months after completion of dosing, patients continue to experience profound clinical benefit, with up to 41% of patients reporting a complete response at 76 weeks and 48% of patients reporting that their disease no longer impacts their quality of life. Barzolvolimab demonstrated a well tolerated safety profile throughout the study. 'In this large Phase 2 study, patients on barzolvolimab experienced rapid, profound, durable complete response which correlated with meaningful improvements in quality of life—the goal of treatment for patients and physicians,' said Martin Metz, M.D., Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and the lead investigator of the study. 'By addressing the root driver of chronic spontaneous urticaria, the mast cell, barzolvolimab provided meaningful clinical benefit to more than 90% of the patients on study, including patients with severe disease refractory to omalizumab, and demonstrated a level of sustained complete response after the completion of active therapy that is unprecedented in CSU. Importantly, across this large, 76 week Phase 2 trial, barzolvolimab also presented a favorable safety profile, further supporting barzolvolimab's significant potential to become a transformative treatment option for patients suffering from this often very severe and debilitating disease.' Data highlights at 76 weeks (7 months/28 weeks after completion of barzolvolimab treatment) Rapid, profound improvements in UAS7 (weekly urticaria activity score) were reported as early as one week after dosing. Barzolvolimab achieved the primary efficacy endpoint, a statistically significant mean change from baseline to Week 12 in UAS7 (weekly urticaria activity score) compared to placebo, at all dose levels. These improvements were sustained or deepened at Week 52 and continued to Week 76. UAS7 mean change from baseline at Week 76 was -20.42 for patients treated with 150 mg Q4W and -21.10 for patients treated with 300 mg Q8W. 41% of patients treated with barzolvolimab 150 mg Q4W and 35% of patients treated with 300 mg Q8W had a complete response (no itch/hives; UAS7=0) at Week 76. 56% of patients treated with barzolvolimab 150 mg Q4W and 47% of patients treated with 300 mg Q8W had well controlled disease (UAS7≤6) at Week 76. 48% of patients treated with barzolvolimab 150 mg Q4W and 40% of patients treated with 300 mg Q8W reported that CSU had no impact on their quality of life at 76 weeks as measured by the Dermatology Life Quality Index (DLQI). Current clinical guidelines recommend complete response (UAS7=0) as the goal of treatment1 and achieving complete response is directly correlated to the greatest improvements in quality of life for patients2. These robust responses and improvements in quality of life were observed regardless of prior omalizumab experience. Barzolvolimab was well tolerated with a favorable safety profile through 76 weeks. The most common adverse events were grade 1 (mild), mechanism related (KIT) and reversible. No new safety signals were identified during the follow-up period. As previously disclosed, neutropenia events resolved rapidly and while still receiving barzolvolimab treatment and there was no association between neutropenia and infections. As expected, neutrophil counts returned to baseline following the completion of barzolvolimab treatment and the mild hair color changes and skin hypopigmentation observed on study were demonstrated to be reversible following discontinuation of treatment. 'At every analysis across multiple endpoints in this Phase 2 study, barzolvolimab has demonstrated best in disease data, suggesting barzolvolimab holds great promise as a transformational treatment for patients suffering from CSU— a disease of misery that often impacts all aspects of patients' lives,' said Diane C. Young, M.D., Senior Vice President and Chief Medical Officer of Celldex. 'On behalf of Celldex, I want to thank the patients and physicians who participated in this study. We remain diligently focused on executing across our clinical trials to bring this potential important new medicine to patients.' Results presented at the EAACI Congress 2025 are available on the "Publications' page of the "Science" section of the Celldex website. 1Zuberbier T, et al. Allergy, 2022; 2Kolkhir P, et al. JACI, 2023 Webcast The Company will host a conference call/webcast today to discuss the results at 6:00 pm ET. To access the live and archived webcast, please visit the Events section on the Investor Relations page of Celldex's website. Parties interested in participating via telephone may register here to receive the dial-in numbers and unique PIN to seamlessly access the call. Otherwise please access the listen-only webcast link. The archived webcast will be available for a limited time on the Company's website. About BarzolvolimabBarzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Barzolvolimab is currently being studied in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), prurigo nodularis (PN), eosinophilic esophagitis (EOE) and atopic dermatitis (AD), with additional indications planned for the future. About the Phase 2 CSU StudyThe randomized, double-blind, placebo-controlled, parallel group Phase 2 study evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy. 208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment period. After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period. After 52 weeks, patients enter a follow-up period for an additional 24 weeks. Barzolvolimab achieved the primary efficacy endpoint of the study—a statistically significant mean change from baseline to week 12 in UAS7 (weekly urticaria activity score) compared to placebo at all dose levels. For additional information on this trial (NCT05368285), please visit About the Phase 3 ProgramCelldex is currently conducting a global Phase 3 Program for barzolvolimab in CSU, consisting of two Phase 3 trials (EMBARQ-CSU1; NCT06445023 and EMBARQ-CSU2; NCT06455202) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. The studies also include patients who remain symptomatic after treatment with biologics. Enrollment is underway. About Chronic Spontaneous Urticaria (CSU)CSU is characterized by the occurrence of hives or wheals for 6 weeks or longer without identifiable specific triggers or causes. The activation of the mast cells in the skin (release of histamines, leukotrienes, chemokines) results in episodes of itchy hives, swelling and inflammation of the skin that can go on for years or even decades. Current therapies provide symptomatic relief only in some patients. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune Forward Looking StatementThis release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & Administration(508) 864-8337scavanaugh@ Patrick TillMeru Advisors(484) 788-8560ptill@
Indianapolis Star
32 minutes ago
- Indianapolis Star
New to The Street Launches Arrive AI TV Commercials Across its Full Media Ecosystem
The campaign will air nationally on CNBC, FOX Business, Bloomberg, and inside NTTS's weekly investor-focused television broadcasts-along with distribution across New to The Street's 2.6M YouTube subscriber channel. NEW YORK CITY, NY / ACCESS Newswire New to The Street, a leading multi-platform financial media brand, proudly announces the launch of a new national commercial campaign for its featured client, Arrive AI (NASDAQ:ARAI). The high-impact TV commercial will be distributed across major financial news networks including CNBC, FOX Business, and Bloomberg, and will be fully integrated into New to The Street's weekly syndicated TV series reaching more than 220 million U.S. homes. View commercial now: The spot will also air across New to The Street's powerful digital network- including its YouTube channel with over 2.6 million subscribers, one of the largest financial video audiences in the world. The campaign shines a spotlight on Arrive AI's patented autonomous delivery platform, emphasizing its smart mailbox technology, U.S. patent portfolio, and its game-changing use cases in healthcare, e-commerce, and temperature-sensitive logistics. It's a critical moment of visibility for the company as it accelerates commercialization and expands across new sectors. 'Arrive AI is one of the most compelling companies we've ever featured,' said Vince Caruso, Creator and Host of New to The Street. 'This TV campaign will bring their message to millions of investors, partners, and consumers across all our channels-network TV, outdoor, digital, and our 2.6M-strong YouTube community. We're proud to help tell their story at scale.' The commercial will be seen: The full-scale media rollout is expected to support upcoming milestones for Arrive AI, including new strategic partnerships, vertical expansion, and additional product announcements. About Arrive AI (NASDAQ:ARAI): Arrive AI is building the future of smart logistics with its patented Arrive Points™ -AI-powered mailboxes designed to securely manage both autonomous and traditional package deliveries. With eight issued patents and a growing presence in healthcare, e-commerce, and industrial delivery, Arrive AI is revolutionizing last-mile fulfillment infrastructure. About New to The Street: New to The Street is a nationally televised business show that features public and private companies, airing as sponsored programming on FOX Business, Bloomberg, and CNBC. It also operates one of the largest financial YouTube channels in the U.S. with over 2.6 million subscribers, supported by robust earned media, digital distribution, and outdoor advertising in Times Square and the NYC Financial District. Media Contact: Monica Brennan PR, New to The Street Monica@ Investor Contact: Dan O'Toole, CEO, Arrive AI ir@ SOURCE: New To The Street View the original press release on ACCESS Newswire
